DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for atransferrinemia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAtransferrinemia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for atransferrinemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Hereditary atransferrinemia has been reported in only 11 patients across 9 families as of 2007, with molecular characterisation completed in just 4 of those cases. The disorder is defined by microcytic anaemia and iron overload. In one US patient, compound heterozygosity was found: a 10-base-pair deletion with a 9-base-pair insertion in one allele, and a G→C transversion at cDNA nucleotide 1429 (predicting an Ala477Pro substitution) in the other. A Turkish patient carried a previously undescribed G→A transition at cDNA 410 (Cys137Tyr) in exon 4. Both mutations occurred at evolutionarily conserved sites and were absent from large control allele screens. Several polymorphisms were also documented, including a silent G→C change at cDNA 1572 and intronic variants, some common and one rare.
A 2022 case report describes acquired atransferrinemia in a 42-year-old woman hospitalised for a relapse of chronic enteropathy. Her serum transferrin was undetectable on admission, yet she exhibited only mild anaemia, and her haemoglobin remained broadly stable over two months despite persistent atransferrinemia. The authors attribute this to a combination of chronic undernutrition, inflammation, and liver failure, and note that the stability of haemoglobin in the absence of detectable transferrin is unexplained. This acquired form appears distinct from the congenital disorder.
A 2025 review emphasises that congenital atransferrinemia can present in early infancy with heart failure due to iron overload cardiomyopathy, severe anaemia, and hepatic or endocrine dysfunction. It states that the condition is treatable and that early diagnosis may prevent progressive myocardial dysfunction and recurrent heart failure. However, the review does not provide new patient data, survival figures, or response rates to any specific intervention. The earlier 2000 report notes that plasma infusions have been used effectively, but no controlled trial data exist.
What remains missing is any systematic trial of treatment, any prospective data on long-term outcomes, and any understanding of why some patients with undetectable transferrin maintain stable haemoglobin. Patient numbers are too small for stratification by genotype or phenotype, and no funding body has supported a multi-centre registry or treatment protocol.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Blood · 2000 · 169 citations
Molecular characterization of a case of atransferrinemia
AbstractHereditary atransferrinemia is a rare but instructive disorder that has previously been reported in only 8 patients in 6 families. It is characterized by microcytic anemia and by iron loading, and can be treated effectively by plasma infusions. We now report the first case known in the United States. We determined the sequences flanking the exons of the human transferrin gene and sequenced all of the exons and some of the flanking regions of the patient's DNA and that of her parents. The patient's DNA revealed a 10-base pair (bp) deletion, followed by a 9-bp insertion of a duplicated sequence. There was also a G-->C transversion at complementary DNA (cDNA) nt 1429, predicting that a proline was substituted for the alanine in amino acid position 477 (Ala 477 Pro). The latter mutation occurs at an evolutionarily highly conserved site; 704 control alleles were screened and this point mutation was not found. Each of the patient's transferrin genes contains one mutation, ie, the patient is a compound heterozygote for these mutations, because one was found in each of her parents. In addition to these mutations, which we regard to be causative in the patient's atransferrinemia, a silent polymorphism at cDNA 1572 G-->C was found in exon 13 as well as 2 previously unreported polymorphisms at IVS8 + 62 c-->t and IVS14-4 c-->a. The mutation in nt 1572 and that in intron 8 were common in the general population; the intron 14 mutation is rare.
A New Case of Human Atransferrinemia with a Previously Undescribed Mutation in the Transferrin Gene
AbstractHereditary atransferrinemia is a very rare disorder characterized by microcytic anemia and iron overload. It has been reported in only 10 patients in 8 families. The molecular basis of atransferrinemia has been determined in only 3 human cases. We now report a new patient with this rare disorder, who is the first known case in Turkey, the 11th patient reported in the published literature and only the 4th case of human atransferrinemia characterized on a molecular basis. DNA analysis of the serum transferrin gene in the patient revealed a previously undescribed mutation in exon 4, a G-->A transition at cDNA 410(Cys137Tyr). A number of previously known polymorphisms and a previously undescribed mutation at IVS10(-23)C-->T, presumably a polymorphism, were also documented.
Molecular characterization of a third case of human atransferrinemia
AbstractAtransferrinemia/hypotransferrinemia is an unusual disorder generally inherited in an autosomal recessive pattern.[1][1],[2][2] The hypochromic, microcytic anemia and hemochromatotic siderosis seen in atransferrinemia/hypotransferrinemia are of interest, as they provide clues to mechanisms and
Biochemia Medica · 2022 · 0 citations · open access
Reversible atransferrinemia in a patient with chronic enteropathy
AbstractHerein, we report the case of a 42-year-old woman, hospitalized in a French tertiary hospital for a relapse of a chronic enteropathy, who was found on admission to have no detectable serum transferrin. Surprisingly, she only exhibited mild anaemia. This atransferrinemia persisted for two months throughout her hospitalization, during which her haemoglobin concentration remained broadly stable. Based on her clinical history and evolution, we concluded to an acquired atransferrinemia secondary to chronic undernutrition, inflammation and liver failure. We discuss the investigations performed in this patient, and hypotheses regarding the relative stability of her haemoglobin concentration despite the absence of detectable transferrin.
Cardiovascular & Haematological Disorders - Drug Targets · 2025 · 0 citations · open access
Revisiting Congenital Atransferrinemia: A Rare but Treatable Cause of Pediatric Heart Failure
AbstractCongenital atransferrinemia is an extremely rare autosomal recessive disorder characterized by functional or quantitative deficiency of transferrin. This leads to a characteristic clinical picture that includes heart failure due to iron overload cardiomyopathy, severe anemia, as well as hepatic and endocrine dysfunction in early infancy. Although rare or may be underdiagnosed, congenital atransferrinemia is a treatable cause of infantile heart failure and iron overload cardiomyopathy. Therefore, it is important to keep this diagnosis as a possibility in childhood presentation of heart failure and anemia. Early diagnosis and timely treatment can prevent progressive myocardial dysfunction and recurrent heart failure. This article focuses on pathophysiology, diagnosis, genetics, and management of heart failure in congenital atransferrinemia.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
